Early studies have shown that changes in FDG uptake on PET scans correlate with treatment response in RET-positive cancers treated with multi-kinase inhibitors that have RET activity like lenvatinib or cabozantinib or vandetanib [12,13,14]. The gene discussed is RET; the disease is cancer.